Physician profile
Relvert J Coe
NPI 1215946637
$307.26
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.98 · 2020: $90.99 · 2021: $117 · 2022: $17.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $92.54 | 2021 | |
| Amgen INC. | $59.03 | 2019-2020 | |
| Novo Nordisk INC | $43.17 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $31.01 | 2019 | |
| Allergan, INC. | $22.33 | 2019-2020 | |
| Abbvie INC. | $17.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.58 | 2019 | |
| Merck Sharp & Dohme LLC | $12.51 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $12.22 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Relvert Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.